United Airlines Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? United Airlines Holdings Inc trades at $118.05 (market cap $38.15B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.2× United Airlines Holdings Inc's market cap. Which is the better fit depends on your goals.
| UAL | VRTX | |
|---|---|---|
Market Cap | $38.15B | $121.95B |
Sector | Industrials | Health |
52-Week High | $136.11 | $529.59 |
52-Week Low | $84.57 | $366.54 |
Enterprise Value | $55.18B | $116.69B |
Trailing returns across standard periods
Latest headlines on both assets
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →